Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies

Merola, J F; Papp, K A; Nash, P; Gratacós, J; Boehncke, Wolf-Henning; Thaçi, D; Graham, D; Hsu, M-A; Wang, C; Wu, J; Young, P

doi:10.1111/jdv.16433

Scientific article

English

Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies

ContributorsMerola, J F; Papp, K A; Nash, P; Gratacós, J; Boehncke, Wolf-Henning; Thaçi, D; Graham, D; Hsu, M-A; Wang, C; Wu, J; Young, P

Published inJournal of the European Academy of Dermatology and Venereology, vol. 34, no. 12, p. 2809-2820

Publication date2020

Abstract

Psoriatic arthritis (PsA) is a chronic, systemic immune-mediated inflammatory musculoskeletal disease. The onset of dermatologic symptoms often precedes rheumatic manifestations. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA that has been shown to improve dermatologic symptoms in patients with PsA.

Keywords

Adult
Arthritis
Psoriatic* / drug therapy
Double-Blind Method
Humans
Piperidines
Psoriasis* / drug therapy
Pyrimidines / therapeutic use
Pyrroles / therapeutic use
Quality of Life
Treatment Outcome

Affiliation entities

Research groups

Inflammation cutanée (919)

Citation (ISO format)

MEROLA, J F et al. Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies. In: Journal of the European Academy of Dermatology and Venereology, 2020, vol. 34, n° 12, p. 2809–2820. doi: 10.1111/jdv.16433

Article (Published version)

CC BY-NC

Identifiers

PID : unige:154820
DOI : 10.1111/jdv.16433
PMID : 32271970

Additional URL for this publicationhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818414/

Journal ISSN0926-9959

179views

156downloads

Creation30/04/2021 15:38:00

First validation30/04/2021 15:38:00

Update time24/01/2025 15:50:28

Status update24/01/2025 15:50:28

Last indexation24/01/2025 15:58:34

Archive ouverte UNIGE

Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies

Technical informations